MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - August 01, 2011) - MorphoSys AG /
AbD Serotec and Merck Sign License Agreement for Use of HuCAL GOLD in
Research. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
research and diagnostic antibody unit AbD Serotec has amended its
license agreement with Merck & Co., Inc. to include the use of MorphoSys's
GOLD technology in the field of vaccines. Under the terms of the
Merck is granted access to HuCAL GOLD for research purposes, with the
upgrade to MorphoSys's latest proprietary antibody library HuCAL
MorphoSys's research and diagnostic antibody segment AbD Serotec will
annual user fees from Merck for access to the HuCAL technology and license
for clinical monitoring reagents. Further financial details were not
"We welcome Merck's decision to continue using the HuCAL technology
research side as a tool to support their vaccine development activities. It
clear sign of the sustained interest of the pharmaceutical industry
leading antibody technology," commented Dieter Feger, Senior Vice
Head of AbD Serotec.
MorphoSys is an independent biotechnology company that develops novel
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical
MorphoSys has created a pipeline of more than 60 drug candidates. The
expanding its drug pipeline by adding new partnered programs, and by
portfolio of fully-owned therapeutic antibodies. For its proprietary
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information,
About AbD Serotec:
AbD Serotec is one of the most reliable, complete sources of research and
diagnostic antibodies in the world. Easy On-line Ordering, With or Without
Credit Card, ISO-certified 2,200 Square Meter Production Facility, Your
AntibodyDetective, More Than 14,000 Catalog Antibodies, Custom Monoclonals
Just 8 Weeks, Antibody Conjugation and Production.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®,
CysDisplay®, RapMAT® and
Slonimics® are registered trademarks of MorphoSys; arYla™ is a
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
Press Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.